About Synnovis

Synnovis is a partnership between SYNLAB UK & Ireland, Guy’s and St Thomas’ NHS Foundation Trust, and King’s College Hospital NHS Foundation Trust. Our organisation brings together the very best in clinical, scientific and operational expertise, and displays in action the core values at the heart of our brand: science for life, collaboration for the benefit of everyone, and innovation and quality.

Synnovis provides services to the NHS, SYNLAB, clinical users and other stakeholders. We are proud to work in collaboration with our excellent partners across our sites. Using innovation and quality to deliver pioneering pathology services is a way of life for us. We have an open and innovative mindset which drives the quality of both our services and the care provided by our clinical service users.

As well as delivering pathology services and in line with the NHS’s own clinical vision and strategy, Synnovis is responsible for transforming existing hospital-based laboratory and diagnostic services into an integrated ‘hub and spoke’ pathology network for south east London.

A state-of-the-art ‘hub’ laboratory has been opened as part of this transformation at Friars Bridge Court, in Blackfriars Road, London, bringing cutting-edge instrumentation, technology and innovation together under one roof. On-site hospital laboratories (the ‘spokes’) will be developed to provide essential services, focusing on the rapid turnaround of urgent tests, such as those needed for A&E departments. The hub is one of the largest, purpose-built pathology laboratories in the UK, designed to meet the needs of modern-day healthcare services.

Synnovis and its partners benefit from SYNLAB’s global laboratory and diagnostic network, which will provides access to a wide range of clinical, scientific and operational expertise, as well as innovative research and development on an international scale.

Synnovis (formerly Viapath) is a founding member of The Association of Independent Pathology Providers (AIPP), which is a trade association representing innovative research-based diagnostic testing companies. The AIPP’s aim is to work at the heart of policy development and decision-making to ensure that patients are able to benefit from the latest and most advanced pathology tests and most efficient processes.